Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data
Open Access
- 12 February 2021
- journal article
- research article
- Published by Association of Basic Medical Sciences of FBIH in Bosnian Journal of Basic Medical Sciences
- Vol. 21 (6), 745-750
- https://doi.org/10.17305/bjbms.2020.5329
Abstract
Kaposi sarcoma is a rare disease and there is a gap in the literature about which chemotherapeutics should be applied, especially for the classical type. We aimed to present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 Kaposi sarcoma (KS) patients treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics, and the chemotherapeutic agents administered to the 16 KS patients diagnosed in our center and treated with chemotherapy, based on the medical records obtained. The median age, gender, type of KS, site of involvement, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4–85.8 years). Among the patients, 1 had immunosuppression-related KS, 4 had AIDS-related KS, and 11 had classical KS. In the first-line cytotoxic therapy, 7 patients received pegylated-liposomal doxorubicin (PLD), 6 patients received paclitaxel, 2 patients received oral etoposide, and 1 patient received the adriamycin, bleomycin, and vincristine regimen. In the Kaplan–Meier analysis, the PFS was 39.9 months (95% CI, 7.7–72.0). In the first-line setting, a significant difference in terms of PFS was observed between the PLD- and paclitaxel-treated groups (not reached vs. 12.8 months, p = 0.033). The OS was 66.1 months (95% CI, 30.2–102.0). The ORR of the 16 patients was 43.8%, and their DCR was 81.3%. No grade 3 or 4 toxicity was observed. This retrospective study showed that PLD seems better than paclitaxel in terms of PFS and response rates and it has shown to have a good safety profile in KS patients.Keywords
This publication has 19 references indexed in Scilit:
- Non-AIDS-related Kaposi's sarcoma: A single-institution experienceWorld Journal of Clinical Oncology, 2013
- Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcomaCancer, 2010
- Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter StudyJournal of Investigative Dermatology, 2008
- Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 casesBritish Journal of Dermatology, 2008
- Pegylated liposomal doxorubicin as second‐line therapy in the treatment of patients with advanced classic Kaposi sarcomaCancer, 2007
- Treatment with taxanes of refractory or life‐threatening Kaposi sarcoma not associated with human immunodeficiency virus infectionCancer, 2006
- Liposomal Pegylated Doxorubicin versus Low-Dose Recombinant Interferon Alfa-2a in the Treatment of Advanced Classic Kaposi's Sarcoma; Retrospective Analysis of Three German CentersCancer Investigation, 2005
- Classical Kaposi sarcomaCancer, 2002
- Seroconversion to Antibodies against Kaposi's Sarcoma–Associated Herpesvirus–Related Latent Nuclear Antigens before the Development of Kaposi's SarcomaThe New England Journal of Medicine, 1996
- Moritz Kaposi: Idiopathic pigmented sarcoma of the skinThe Journal of Emergency Medicine, 1995